Dynamic glycemic exposure and trajectory profiling for incident diabetic kidney disease: A longitudinal cohort study

Table 4 Association between glycated hemoglobin trajectories and the risk of incident diabetic kidney disease

HbA1c trajectory	Model 1		Model 2		Model 3
	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value
Low-stable (group 1)	Reference		Reference		Reference
Quickly declining-stable (group 2)	1.73 (1.09-2.73)	0.020	1.79 (1.13-2.84)	0.013	1.57 (0.95-2.58)	0.076
Quickly increasing-stable (group 3)	3.83 (2.62-5.60)	< 0.001	3.92 (2.68-5.73)	< 0.001	3.62 (2.41-5.43)	< 0.001
High-slow decline (group 4)	6.02 (4.48-8.09)	< 0.001	5.69 (4.22-7.67)	< 0.001	4.72 (3.29-6.77)	< 0.001

Model 1 unadjusted model; model 2 adjusted for age and sex; model 3 adjusted for age, sex, body mass index, hypertension, major adverse cardiovascular and cerebrovascular events, hyperlipidemia, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment, diabetes duration, blood urea nitrogen, serum creatinine, uric acid, low-density lipoprotein cholesterol, lipoprotein(a), urine albumin-to-creatinine ratio and measurement intensity. HbA1c: Glycated hemoglobin; CI: Confidence interval; HR: Hazard ratio.